Back to Browse Journals » Neuropsychiatric Disease and Treatment » Volume 6 » Issue 1

Antipsychotic treatments for the elderly: efficacy and safety of aripiprazole

Authors Izchak Kohen, Paula E Lester, Sum Lam

Published Date March 2010 Volume 2010:6(1) Pages 47—58

DOI http://dx.doi.org/10.2147/NDT.S6411

Published 2 March 2010

Izchak Kohen1, Paula E Lester2, Sum Lam3

1Division of Geriatric Psychiatry, Zucker-Hillside Hospital, Glen Oaks, NY, USA; 2Division of Geriatric Medicine, Winthrop University Hospital, Mineola, NY, USA; 3Division of Pharmacy and Geriatrics, St. John’s University College of Pharmacy and Allied Health Professions, Queens, NY, USA

Abstract: Delusions, hallucinations and other psychotic symptoms can accompany a number of conditions in late life. As such, elderly patients are commonly prescribed antipsychotic medications for the treatment of psychosis in both acute and chronic conditions. Those conditions include schizophrenia, bipolar disorder, depression and dementia. Elderly patients are at an increased risk of adverse events from antipsychotic medications because of age-related pharmacodynamic and pharmacokinetic changes as well as polypharmacy. Drug selection should be individualized to the patient’s previous history of antipsychotic use, current medical conditions, potential drug interactions, and potential side effects of the antipsychotic. Specifically, metabolic side effects should be closely monitored in this population. This paper provides a review of aripiprazole, a newer second generation antipsychotic agent, for its use in a variety of psychiatric disorders in the elderly including schizophrenia, bipolar disorder, dementia, Parkinson’s disease and depression. We will review the pharmacokinetics and pharmacodynamics of aripiprazole as well as dosing, diagnostic indications, efficacy studies, and tolerability including its metabolic profile. We will also detail patient focused perspectives including quality of life, patient satisfaction and adherence.
Keywords: aripiprazole, antipsychotics, elderly, adverse drug reaction

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

An economic evaluation of aripiprazole vs olanzapine adapted to the Italian setting using outcomes of metabolic syndrome and risk for diabetes in patients with schizophrenia

Giorgio L Colombo, Mauro Caruggi, Sergio Di Matteo, Alessandro Rossi

Neuropsychiatric Disease and Treatment 2008, 4:967-976

Published Date: 28 August 2008

Applications of gold nanoparticles in cancer nanotechnology

Weibo Cai, Ting Gao, Hao Hong, Jiangtao Sun

Nanotechnology, Science and Applications 2008, 1:17-32

Published Date: 19 September 2008

Treatment and prevention of mania in bipolar I disorder: focus on aripiprazole

David J Muzina

Neuropsychiatric Disease and Treatment 2009, 5:279-288

Published Date: 19 May 2009

Aripiprazole for late-life schizophrenia

Jeffrey Rado, Philip G Janicak

Clinical Interventions in Aging 2010, 5:253-258

Published Date: 30 August 2010

Lyme disease: the next decade

Raphael B Stricker, Lorraine Johnson

Infection and Drug Resistance 2011, 4:1-9

Published Date: 7 January 2011

Long-term treatment of bipolar disorder with a radioelectric asymmetric conveyor

Mannu P, Rinaldi S, Fontani V, Castagna A

Neuropsychiatric Disease and Treatment 2011, 7:373-379

Published Date: 15 June 2011

The discrediting of the monoamine hypothesis

Hinz M, Stein A, Uncini T

International Journal of General Medicine 2012, 5:135-142

Published Date: 14 February 2012

Characterization and evolution of dermal filaments from patients with Morgellons disease

Middelveen MJ, Mayne PJ, Kahn DG, Stricker RB

Clinical, Cosmetic and Investigational Dermatology 2013, 6:1-21

Published Date: 8 January 2013